Abstract
Atrial fibrillation (AF), one of the most prevalent supra-ventricular arrhythmia in adults, is related to a substantial increase in the risk of thromboembolic events requiring tailored preventive strategy. In AF, antithrombotic therapy should be individualized according to a careful decisionmaking process, taking in account the likely concomitant presence of risk factors for stroke and bleeding. Anticoagulation management is particularly challenging in women with AF, to the extent that female sex is incorporated in commonly used stratification schemes for both thromboembolic and bleeding risk evaluation. Nevertheless, gender- based differences on the efficacy and safety of either “old” (i.e. vitamin K antagonist) or “new” oral anticoagulants (i.e. direct thrombin inhibitors and activated factor X inhibitors) are not conclusive and not always reported. This review aims to analyse the literature on sex differences in AF anticoagulation management. We focus on safety data, bleeding complications and specific haemostatic mechanisms currently under investigation, which could account for observed disparities among sexes. Moreover, details on sex difference in response to anticoagulant treatment will be discussed. Comparing old and new antithrombotics, a need clearly emerges for differentiated and integrated strategies for the treatment of AF in female patients.
Keywords: Atrial fibrillation, anticoagulant therapy, gender differences, new oral anticoagulants.
Current Vascular Pharmacology
Title:Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women
Volume: 13 Issue: 6
Author(s): Stefania Basili, Valeria Raparelli, Marco Proietti, Laura Napoleone, Patrizia Ferroni and Flavia Franconi
Affiliation:
Keywords: Atrial fibrillation, anticoagulant therapy, gender differences, new oral anticoagulants.
Abstract: Atrial fibrillation (AF), one of the most prevalent supra-ventricular arrhythmia in adults, is related to a substantial increase in the risk of thromboembolic events requiring tailored preventive strategy. In AF, antithrombotic therapy should be individualized according to a careful decisionmaking process, taking in account the likely concomitant presence of risk factors for stroke and bleeding. Anticoagulation management is particularly challenging in women with AF, to the extent that female sex is incorporated in commonly used stratification schemes for both thromboembolic and bleeding risk evaluation. Nevertheless, gender- based differences on the efficacy and safety of either “old” (i.e. vitamin K antagonist) or “new” oral anticoagulants (i.e. direct thrombin inhibitors and activated factor X inhibitors) are not conclusive and not always reported. This review aims to analyse the literature on sex differences in AF anticoagulation management. We focus on safety data, bleeding complications and specific haemostatic mechanisms currently under investigation, which could account for observed disparities among sexes. Moreover, details on sex difference in response to anticoagulant treatment will be discussed. Comparing old and new antithrombotics, a need clearly emerges for differentiated and integrated strategies for the treatment of AF in female patients.
Export Options
About this article
Cite this article as:
Basili Stefania, Raparelli Valeria, Proietti Marco, Napoleone Laura, Ferroni Patrizia and Franconi Flavia, Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women, Current Vascular Pharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570161113666150216152054
DOI https://dx.doi.org/10.2174/1570161113666150216152054 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Pharmacoproteomics Studies of Warfarin in the Asia-Pacific: A New Strategy for Personalized Medicine?
Current Pharmacogenomics and Personalized Medicine Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Syndrome of Supine Hypertension with Orthostatic Hypotension: Pathophysiology and Clinical Approach
Current Cardiology Reviews Radionuclide Imaging in Drug Development
Current Pharmaceutical Design Secondary Prevention of Ischemic Stroke
Current Drug Targets Phytochemicals as Inhibitors of Candida Biofilm
Current Pharmaceutical Design Evolution and Analysis of Heterogeneity in the Clinical Expression of Aortic Diseases Similar to Marfan’s Syndrome: Challenge and Art in Clinical Diagnosis
Current Rheumatology Reviews Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Coarctation of the Aorta - An Evolution of Therapeutic Options
Current Cardiology Reviews Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases
Current Medicinal Chemistry Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Statins and Inflammation in Cardiovascular Disease
Current Pharmaceutical Design Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Conduction Disorders: The Value of Surface ECG
Current Cardiology Reviews Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry Monochloramine Use for Prevention of Legionella in Hospital Water Systems.
Infectious Disorders - Drug Targets 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry